Transcranial Focused Ultrasound Mitigates Ischemic Neuroinflammation via the Nespas/miR-383-3p/Shp2 Pathway

Study Background and Research Question

Acute ischemic stroke remains a leading cause of disability and mortality worldwide, with limited therapeutic options due to the narrow window for thrombolytic intervention and the complexities of secondary brain injury. Neuroinflammation, particularly mediated by microglial activation and the NLRP3 inflammasome, has emerged as a central driver of post-stroke pathology, exacerbating neuronal loss and impeding recovery. Recent evidence suggests non-invasive neuromodulation techniques such as transcranial focused ultrasound stimulation (tFUS) may attenuate neuroinflammatory responses, but the molecular mechanisms underlying these effects have not been fully elucidated. The reference study (Hong et al., 2025) addresses this knowledge gap by investigating how tFUS modulates neuroinflammation after ischemic stroke, focusing on the Nespas/miR-383-3p/SHP2 signaling pathway.

Key Innovation from the Reference Study

The core innovation of this research lies in delineating an epigenetic and post-transcriptional regulatory axis—Nespas/miR-383-3p/SHP2—that mediates the neuroprotective effects of tFUS in a rat model of ischemic stroke. Unlike previous studies that broadly characterized anti-inflammatory effects, this work identifies Nespas, a long non-coding RNA, as a key upstream regulator that, through miR-383-3p, modulates the expression and activity of Shp2, a protein tyrosine phosphatase known for its involvement in cellular signaling, including the regulation of inflammasome activation. The demonstration that tFUS exerts its anti-neuroinflammatory action by upregulating Nespas, thereby suppressing NLRP3 activation via Shp2, represents a significant mechanistic advance.

Methods and Experimental Design Insights

To dissect the neuroprotective mechanism of tFUS, the investigators employed a transient middle cerebral artery occlusion (MCAO) model in rats to induce focal cerebral ischemia. Low-intensity tFUS was delivered to the ischemic hemisphere starting 24 hours after stroke induction and continued daily for seven days. Neurological outcomes were assessed using standardized behavioral tests, while infarct volumes were quantified histologically. To probe the molecular mechanisms, the study combined several approaches:

• Western blotting, immunofluorescence, and qRT-PCR to measure protein and RNA expression levels of NLRP3, Nespas, miR-383-3p, and Shp2 in brain tissue and microglial BV2 cells.
• RNA sequencing to explore transcriptomic changes post-tFUS.
• Cellular models of oxygen-glucose deprivation/reperfusion (OGD/R) to mimic ischemic injury in vitro.
• siRNA-mediated silencing of Nespas and pharmacological inhibition of Shp2 to dissect pathway specificity.

Importantly, the use of both in vivo and in vitro models allowed the authors to link behavioral outcomes to molecular and cellular mechanisms, strengthening the translational relevance of their findings.

Core Findings and Why They Matter

The study yielded several key findings:

• tFUS significantly improved neurobehavioral outcomes and reduced infarct size in post-stroke rats.
• tFUS suppressed NLRP3 inflammasome activation and reduced pro-inflammatory cytokine production.
• Nespas expression was markedly increased in tFUS-treated animals, and silencing Nespas reversed the neuroprotective effects and heightened NLRP3 activation.
• Nespas positively regulated Shp2 expression via miR-383-3p; inhibition of Shp2 amplified NLRP3-driven neuroinflammation, confirming Shp2’s central role in this axis.

Together, these results show that the reference study provides mechanistic evidence that tFUS mitigates post-ischemic neuroinflammation by enhancing the Nespas/miR-383-3p/Shp2 pathway. This insight positions Shp2 as a critical modulator of microglial NLRP3 activation, highlighting its potential as a research target for both pharmacological and bioengineering strategies in neuroinflammation and stroke recovery.

Comparison with Existing Internal Articles

The mechanistic emphasis on Shp2 in this paper builds on and complements recent internal reviews of Shp2 inhibition strategies. For instance, "NSC 87877: Shp2 Inhibition Strategies in Translational Neuroinflammation" discusses how selective Shp2 inhibitors such as NSC 87877 can be used to dissect the Nespas/miR-383-3p/SHP2 axis in experimental neuroinflammation. The article provides protocol guidance for integrating Shp2 pathway inhibitors into neuroinflammation models, referencing both in vitro microglial assays and in vivo ischemic stroke workflows. Likewise, "NSC 87877: Transforming Neuroinflammation Research with Shp2 Inhibition" offers a translational perspective, highlighting how tools like NSC 87877 enable mechanistic validation of Shp2’s role in NLRP3 inflammasome regulation, as demonstrated in the current reference study. The convergence of evidence across these sources supports the value of selective Shp2 inhibition for probing neuroinflammatory signaling and therapeutic development.

Limitations and Transferability

While the study provides strong mechanistic evidence linking tFUS, Nespas, and Shp2 to reduced neuroinflammation, several limitations merit consideration. The work is based primarily on rodent models, and while these provide valuable insight into cellular mechanisms, species differences may affect translation to human stroke pathology. The use of pharmacological Shp2 inhibition and RNA silencing in cell lines offers molecular specificity, but in vivo selectivity and off-target effects remain potential confounders. Additionally, the study focuses on the acute phase post-stroke; the durability and broader applicability of tFUS-induced molecular changes over longer recovery periods require further validation. Finally, the exclusive focus on the Nespas/miR-383-3p/SHP2/NLRP3 axis, while mechanistically informative, does not exclude the involvement of other parallel or interacting pathways in tFUS-mediated neuroprotection.

Protocol Parameters

• tFUS application: Low-intensity, targeted to the ischemic hemisphere, initiated 24 hours post-MCAO and continued daily for 7 days (as per Hong et al., 2025).
• Shp2 inhibition (literature reports): Application of selective Shp2 inhibitors in cell-based OGD/R models to assess pathway specificity (see internal comparisons for NSC 87877 experimental context).
• Genetic modulation: siRNA-mediated silencing of Nespas and miR-383-3p to delineate pathway roles; recommended for mechanistic studies but requires optimization for in vivo use.

Research Support Resources

Researchers interested in replicating or extending these findings can employ selective Shp2 inhibitors to interrogate the Nespas/miR-383-3p/SHP2 axis in neuroinflammatory models. NSC 87877 (SKU A4544) from APExBIO is a well-characterized, potent, and selective Shp2 inhibitor with documented utility in studies of neuroinflammation, EGF-induced Erk1/2 activation, and leukemia cell line cytotoxicity. According to the product information, NSC 87877 exhibits low micromolar IC50 values against Shp2 and Shp1, with high selectivity over related phosphatases, making it suitable for dissecting Shp2-dependent pathways in both cellular and animal models. For detailed guidance on integrating Shp2 inhibitors into translational neuroinflammation workflows, see this internal review.